Skip to main content

Table 1 Patient attributes

From: Impact of pharmacist counseling on reducing instances of adverse events that can affect the quality of life of chemotherapy outpatients with breast Cancer

Item

Non intervention

Intervention

P

n (%)

n (%)

Age (year)

 Mean ± Standard deviation

53.3 ± 11.1

56.3 ± 9.0

0.313

Gender

 Female

19 (100)

20 (100)

1.000

 Male

0 (0)

0 (0)

PS

 0

19 (100)

20 (100)

1.000

 1

0 (0)

0 (0)

 2

0 (0)

0 (0)

Stage

 I

3 (16.7)

8 (38.1)

0.238

 II

8 (44.4)

11 (52.4)

 III

5 (22.2)

2 (9.5)

 IV

3 (16.7)

0 (0)

HER2

 0

1 (5.6)

1 (4.8)

0.213

 + 1

9 (44.4)

13 (61.9)

 + 2

6 (33.3)

2 (9.5)

 FISH-

4

2

 FISH+

2

 

 + 3

3 (16.7)

5 (23.8)

ER

   

 +

15 (77.8)

15 (71.4)

0.223

 ±

2 (11.1)

4 (19.0)

 –

2 (11.1)

2 (9.5)

PgR

   

 +

10 (55.6)

11 (52.4)

0.223

 ±

4 (16.7)

5 (23.8)

 –

5 (27.8)

5 (23.8)

Purpose of chemotherapy

   

 Neoadjuvant

11 (61.1)

8 (40.0)

0.343

 Adjuvant

8 (38.9)

12 (60.0)

Regimen

   

 Anthracyclines

  

0.110

  EC (every 3w)

11 (61.1)

11 (55.0)

  FEC (every 3w)

0 (0)

3 (15.0)

 Taxanes

  

  TC (every 3w)

3 (16.7)

6 (30.0)

  nabPTX (every 3w)

1 (5.6)

0 (0)

  PTX + BV (every 4w)

1 (5.6)

0 (0)

 Others

  

  CMF (every 3w)

3 (16.7)

0 (0)

Marital status

   

 Married

13 (68.4)

16 (80.0)

0.480

 Unmarried

6 (31.6)

4 (20.0)

Cohabitants

   

 Yes

19 (100)

19 (95.0)

1.000

 No

0 (0)

1 (5.0)

Current occupation

   

 Employer

12 (63.2)

9 (45.0)

0.341

 Non-employee

7 (36.8)

11 (55.0)

  1. Fisher’s exact test, PS performance status, HER2 human epidermal growth factor receptor type 2, ER estrogen receptor, PgR progesterone receptor, EC epirubicin/cyclophosphamide, FEC fluorouracil/epirubicin/cyclophosphamide, TC docetaxel/cyclophosphamide, nab-PTX nanoparticle albumin-bound paclitaxel, PTX paclitaxel, BV Bevacizumab, CMF cyclophosphamide/methotrexate/fluorouracil